Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

2(50.0%)

Phase 4

1(25.0%)

N/A

1(25.0%)

4Total

Phase 3(2)

Phase 4(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT02947438Phase 3Completed

Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)

Role: collaborator

NCT01853163Not ApplicableCompleted

Long-Term Retention of Gadolinium in Bone

Role: lead

NCT02522975Phase 4Terminated

Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study)

Role: collaborator

NCT00463450Phase 3Completed

Efficacy of Gynodian® Depot in Women With Impaired Well-being

Role: collaborator

All 4 trials loaded